

Autism Spectrum Disorder Diagnoses and Congenital Cytomegalovirus

Megan H. Pesch, MD, MS,^a Jessica Leung, MPH,^b Tatiana M. Lanzieri, MD, MPH,^b Sarah C. Tinker, PhD,^c Charles E. Rose, PhD,^c Melissa L. Danielson, MSPH,^c Marshalyne Yeargin-Allsopp, MD,^c Scott D. Grosse, PhD^c

abstract

OBJECTIVE: To examine the association between congenital cytomegalovirus (cCMV) and autism spectrum disorder (ASD) administrative diagnoses in US children.

METHODS: Cohort study using 2014 to 2020 Medicaid claims data. We used diagnosis codes to identify cCMV (exposure), ASD (outcome), and covariates among children enrolled from birth through ≥ 4 to < 7 years. Covariates include central nervous system (CNS) anomaly or injury diagnosis codes, including brain anomaly, microcephaly within 45 days of birth, cerebral palsy, epilepsy, or chorioretinitis. We used Cox proportional hazards regression models to estimate hazard ratios and 95% confidence intervals, overall and stratified by sex, birth weight and gestational age outcome (low birth weight or preterm birth), and presence of CNS anomaly or injury.

RESULTS: Among 2 989 659 children, we identified 1044 (3.5 per 10 000) children with cCMV and 74 872 (25.0 per 1000) children with ASD. Of those with cCMV, 49% also had CNS anomaly or injury diagnosis codes. Children with cCMV were more likely to have ASD diagnoses (hazard ratio: 2.5; 95% confidence interval: 2.0–3.2, adjusting for birth year, sex, and region). This association differed by sex and absence of CNS anomaly or injury but not birth outcome.

CONCLUSIONS: Children with (versus without) cCMV diagnoses in Medicaid claims data, most of whom likely had symptomatic cCMV, were more likely to have ASD diagnoses. Future research investigating ASD risk among cohorts identified through universal cCMV screening may help elucidate these observed associations.



^aDivision of Developmental and Behavioral Pediatrics, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan; and ^bNational Center for Immunization and Respiratory Diseases, and ^cNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia

Drs Pesch, Grosse, and Lanzieri conceptualized and designed the study, contributed to data interpretation, and drafted the initial manuscript; Ms Leung conceptualized and designed the study, performed the data analysis, contributed to data interpretation, and drafted the initial manuscript; Drs Tinker and Yeargin-Allsopp conceptualized and designed the study and contributed to data interpretation; Dr Rose and Ms Danielson designed the study and the data analysis and contributed to data interpretation; and all authors critically reviewed and revised the manuscript, approved the final manuscript as submitted, and agree to be accountable for all aspects of the work.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

DOI: <https://doi.org/10.1542/peds.2023-064081>

Accepted for publication Mar 21, 2024

Address correspondence to Megan H. Pesch, MD, MS, Division of Developmental and Behavioral Pediatrics, University of Michigan, NCRC B520 2800 Plymouth Rd, Ann Arbor, MI 48109-2800. E-mail: pesch@umich.edu

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

WHAT'S KNOWN ON THIS SUBJECT: Children with congenital cytomegalovirus (cCMV) are at higher risk of neurodevelopmental sequelae. The authors of some small studies have reported a higher prevalence of autism spectrum disorder among children with cCMV than in uninfected children.

WHAT THIS STUDY ADDS: In this analysis of US administrative claims data, children with a diagnosis of cCMV were 2.5 times as likely as children without that diagnosis to also have a diagnosis of autism spectrum disorder.

To cite: Pesch MH, Leung J, Lanzieri TM, et al. Autism Spectrum Disorder Diagnoses and Congenital Cytomegalovirus. *Pediatrics*. 2024;153(6):e2023064081

Congenital cytomegalovirus (cCMV) is the most common congenital infection in the United States, affecting 1 in every 200 live births.^{1,2} Approximately 10% of infants with cCMV are born with symptomatic disease (eg, clinical, laboratory, or brain imaging abnormalities), which is associated with heightened risk of cerebral palsy, epilepsy, intellectual disability, and sensorineural hearing loss.^{3,4} Additionally, as many as 15% of children with asymptomatic cCMV infection develop sensorineural hearing loss by age 5 years.⁵ Some US states and Canadian provinces have recently begun to implement universal cCMV screening programs, which provide an opportunity for early intervention.⁶

Autism spectrum disorder (ASD) is a developmental disability that manifests as persistent difficulties with social communication and restricted, repetitive behaviors.⁷ A 2020 estimate of prevalence across multiple US sites was 27.6 of 1000 8 year olds.⁸ Its etiology is likely influenced by diverse genetic and environmental factors, including the intrauterine environment.^{9,10} Possible associations between certain prenatal exposures to some viruses and risk of ASD in offspring have been reported.^{11–13} It has been hypothesized that infections may contribute to perinatal neuroinflammation, which in turn may alter the expression of genes conferring ASD risk.^{9,14}

A cooccurrence of prenatal cytomegalovirus (CMV) infection or cCMV with risk of ASD has been reported in several case series or case-control studies, with ASD ~2 to 3 times more common in children with cCMV and cCMV up to 10 times more common in children with ASD.^{15–19,24,25} However, the numbers of children with both cCMV and ASD in these studies were small, including 4 or fewer children with both cCMV and ASD, and differences were not always statistically significant.^{19,20} A summary of peer-reviewed publications reporting on the cooccurrence of cCMV and ASD is provided in Supplemental Table 3. Studies have revealed that children born with brain anomalies or disturbances in utero from a variety of causes have a higher risk of ASD because of alterations in fetal central nervous system (CNS) organogenesis and synapse formation.⁹ cCMV has likewise been associated with CNS injury and anomalies, due to the virus's neurophilic nature, which enables the disruption of typical fetal brain development.^{21–23}

In this study, using a large US administrative claims data set, we assessed the administrative prevalence of ASD diagnosis in young children with and without a cCMV diagnosis, overall and stratified by other conditions associated with increased risk of ASD diagnosis (eg, preterm birth, low birth weight [LBW], and CNS anomaly or injury).^{26,27}

METHODS

Data Source

We used 2014 to 2020 administrative data from the Transformed Medicaid Statistical Information System

Analytic Files database from the Centers for Medicare and Medicaid Services, which includes information on enrollment, inpatient and outpatient services, and outpatient drug claims. Deidentified data on >100 million Americans, including children and pregnant women, enrolled in state Medicaid or Children's Health Insurance Program (CHIP) plans are included in the database. The use of this database was determined not to require institutional review board approval.

Study Population and Definitions

Our study population consisted of children who were continuously enrolled in Medicaid or CHIP from birth through ≥ 4 to <7 years. Children with cCMV were identified by the presence of an *International Classification of Diseases, Ninth or Tenth Revisions, Clinical Modification* diagnostic code for cCMV infection (771.1, P35.1) or cytomegaloviral disease (078.5, B25.x) recorded within 45 days of birth, as in our previous studies.^{28–30} ASD was defined as 2 or more inpatient or outpatient visits with diagnostic codes for ASD (299.0x, 299.8x, 299.9x, F84.0, F84.5, F84.8, F84.9) ≥ 6 days apart at a minimum age of 1 year (Supplemental Table 4).³¹ The date of the first ASD diagnostic code was used at the time of initial ASD diagnosis.

We assessed the presence of cooccurring diagnoses that have been reported to be associated with cCMV and ASD, including preterm birth, LBW, hearing loss, and CNS anomaly or injury defined as diagnoses of brain anomaly, microcephaly within 45 days of birth, cerebral palsy, epilepsy, or chorioretinitis (Supplemental Table 4).^{32–35}

Analysis

We calculated the prevalence and 95% confidence intervals (CIs) of cCMV and ASD by sex, region, birth outcomes (preterm birth and LBW, preterm birth only, LBW only, or neither), the presence of individual or collective CNS anomaly or injury codes, and hearing loss.

We used Cox proportional hazards regression models to estimate hazard ratios (HRs) and 95% CIs for ASD in children with and without cCMV, overall, adjusted for birth year, region, and sex. We also conducted stratified analyses by sex, combinations of preterm birth and LBW, and presence of any CNS anomaly or injury to assess potential differences by these characteristics. We elected not to adjust for race and ethnicity in our primary analysis because of missingness of this variable (24%) but included it in a complete-case sensitivity analysis with the 76% of the sample with non-missing values (Supplemental Table 5).

We generated a Kaplan–Meier curve to compare the risk of having a diagnosis of ASD among children with and without cCMV over time. Observation time started at birth. Children who met the ASD case definition were censored when the first ASD diagnostic code was recorded,

and others who did not experience the event, ASD diagnosis, were censored at either death, disenrollment, or the end of the study period follow-up time. For all analyses, we used SAS version 9.3 (SAS Institute Inc, Cary, NC).

RESULTS

A total of 2 989 659 children who were continuously enrolled in Medicaid or CHIP from birth through ≥ 4 to < 7 years were included in this analysis. Overall, we identified 1044 (3.5 per 10 000) children with cCMV and 74 872 (25.0 per 1000) children with ASD (Table 1; Supplemental Fig 2). The administrative prevalence (prevalence of diagnoses) of cCMV was similar by sex but varied by region, with lower prevalence in the West as compared with other regions. The prevalence of diagnosed ASD was higher in males than in females (37.2 vs 12.3 per 1000 children) and in the Northeast as compared with other regions.

The prevalences of both cCMV and ASD diagnoses were higher among children with diagnoses of preterm birth and LBW, LBW only, or preterm birth only, compared with children who were not coded as either preterm birth or LBW (Table 1). The prevalences of CNS anomaly or injury codes and hearing loss were also higher among children diagnosed with cCMV or ASD. For example, hearing loss was 45 times and 5 times as prevalent among children with cCMV and ASD than among those without those diagnoses, respectively.

The Kaplan–Meier curve revealed that children with a cCMV diagnosis were more likely to subsequently have a diagnosis of ASD (Fig 1). Among those who had an ASD diagnosis, the median age at the first claim with an ASD diagnosis was 39 (interquartile range: 31–50) months for children with a cCMV diagnosis and 37 (interquartile range: 30–45) months for children without a cCMV diagnosis. The overall prevalence of ASD diagnosis at the end of the study period was 64.2 (95% CI: 49.3–79.0) per 1000 for children with a cCMV diagnosis and 25.0 (95% CI: 24.9–25.2) per 1000 for children without a cCMV diagnosis (Table 1).

The unadjusted HR for having a diagnosis of ASD was 2.61 (95% CI: 2.03–3.28) comparing children with and without cCMV. The HR adjusted for birth year, region, and sex was 2.54 (95% CI: 1.98–3.19; Table 2). Stratification by sex revealed a much stronger association between cCMV and ASD was observed for females (adjusted HR: 4.65; 95% CI: 3.09–6.59) than for males (adjusted HR: 1.95; 95% CI: 1.40–2.61). Stratification by preterm birth and LBW resulted in slightly lower adjusted HRs (1.79 to 2.15). Stratification by CNS anomaly or injury revealed larger (but not statistically significant) differences with an adjusted HR of an ASD diagnosis among children diagnosed with cCMV of 1.00 (95% CI: 0.74–1.31) in the stratum with CNS anomaly or injury and of 1.60 (95% CI: 0.99–2.40) than in the stratum without any CNS anomaly or injury.

In a sensitivity analysis in which race and ethnicity was included for the subset of cases with non-missing race and ethnicity records, the overall association changed from HR 2.45 to adjusted hazard ratio 2.65 (95% CI: 1.94–3.51; Supplemental Table 5).

DISCUSSION

In this study of administrative claims data for nearly 3 million children enrolled in Medicaid or CHIP, we found that children with a cCMV diagnosis were ~ 2.5 times as likely to have an ASD diagnosis compared with children without cCMV. Although there was no association between cCMV and ASD diagnoses among children who had CNS anomaly or injury, the likelihood of an ASD diagnosis among children with cCMV diagnoses was 1.6 times greater for children without cCMV among children without CNS anomaly or injury codes. Although the association between cCMV and ASD diagnosis was not statistically significant for those with or without CNS injury, the HR reduced substantially when stratifying by CNS involvement. These results are consistent with some, but not all, of the association between cCMV and ASD potentially being attributable to brain anomalies caused by cCMV. In addition, when we stratified by preterm birth or LBW, the likelihood of an ASD diagnosis among children with cCMV was approximately twice that of children without cCMV in all strata. Our findings suggest that even among children with cCMV who are not born with brain anomalies or preterm +/– LBW, an increased risk for ASD is still observed.

When our models were stratified by sex, we found the risk of having an ASD diagnosis in females with a cCMV diagnosis was 4.6 times greater than of those without a cCMV diagnosis, and nearly 2 times higher in boys with a cCMV diagnosis. In general, neurodevelopmental disorders, such as ASD, disproportionately affect males, which has been hypothesized to be due to genetic factors (eg, X-linked genetic conditions) and sex hormone involvement.^{36,37} It may be that children with cCMV receive more neurodevelopmental surveillance and services at baseline and may be more likely to receive a diagnosis of ASD, whereas ASD is thought to be underdiagnosed in the general population of girls because of more subtle and nonstereotypical presentations.^{38,39}

Maternal CMV infection can activate an inflammatory state which may, in turn, impact fetal brain development, thereby increasing the risk of ASD.¹³ In the most severely affected pregnancies, the virus may enter and replicate in fetal CNS cells, leading to alterations in embryogenesis.^{40,41} These differences in CNS development in utero may, in some cases, be subtle and not manifest as visible pathology on neuroimaging or as medical conditions such as cerebral palsy or epilepsy. The authors of previous studies have suggested that children with symptomatic cCMV may be at particularly elevated risk of ASD.^{19,20} We found that the overall prevalence of ASD diagnosis was

TABLE 1 Prevalence of cCMV and ASD Among US Children Enrolled in Medicaid by Sex, Region, and Clinical Characteristics, Medicaid, 2014 to 2020

Characteristics	Total No. of Children	cCMV ^a		ASD ^b	
		n (%)	Prevalence per 10 000 (95% CI)	n (%)	Prevalence per 1000 (95% CI)
Total	2 989 659	1044 (100)	3.5 (3.3–3.7)	74 872 (100)	25.0 (24.9–25.2)
Sex					
Female	1 460 253 (49)	477 (46)	3.3 (3.0–3.6)	17 924 (24)	12.3 (12.1–12.5)
Male	1 529 383 (51)	567 (54)	3.7 (3.4–4.0)	56 948 (76)	37.2 (36.9–37.5)
Region					
Northeast	295 765 (10)	105 (10)	3.6 (2.9–4.3)	11 341 (15)	38.3 (37.6–39.1)
North Central	599 916 (20)	234 (22)	3.9 (3.4–4.4)	13 109 (18)	21.9 (21.5–22.2)
South	1 495 492 (50)	564 (54)	3.8 (3.5–4.1)	36 488 (49)	24.4 (24.1–24.7)
West	579 747 (19)	139 (13)	2.4 (2.0–2.8)	13 688 (18)	23.6 (23.2–24.0)
Birth outcomes					
Preterm birth and LBW	131 975 (4)	369 (35)	28.0 (25.2–31.0)	4893 (7)	37.1 (36.1–38.1)
LBW only	51 568 (2)	175 (17)	33.9 (29.3–39.4)	1502 (2)	29.1 (27.7–30.6)
Preterm birth only	122 218 (4)	103 (10)	8.4 (6.9–10.2)	3874 (5)	31.7 (30.7–32.7)
Neither preterm birth nor LBW	2 683 898 (90)	397 (38)	1.5 (1.3–1.6)	64 603 (86)	24.1 (23.9–24.3)
Any CNS anomaly/injury ^c					
Yes	87 430 (3)	511 (49)	58.4 (53.6–63.7)	8150 (11)	93.2 (91.2–95.3)
No	2 902 229 (97)	533 (51)	1.8 (1.7–2.0)	66 722 (89)	23.0 (22.8–23.2)
Brain anomaly					
Yes	37 488 (1)	367 (35)	97.9 (89.6–107.1)	3289 (4)	87.7 (84.8–90.8)
No	2 952 171 (99)	677 (65)	2.3 (1.8–2.1)	71 583 (96)	24.2 (24.1–24.4)
Microcephaly					
Yes	2846 (0)	88 (8)	309.2 (250.9–381.1)	98 (0.1)	34.4 (28.2–42.0)
No	2 986 813 (100)	956 (92)	3.2 (3.0–3.4)	74 774 (99.9)	25.0 (24.9–25.2)
Cerebral palsy					
Yes	13 086 (0)	222 (21)	169.6 (148.7–193.5)	1416 ((2)	108.2 (102.7–114.0)
No	2 976 573 (100)	822 (79)	2.8 (2.6–3.0)	73 456 (98)	24.7 (24.5–24.9)
Epilepsy					
Yes	51 615 (2)	205 (20)	39.7 (34.6–45.5)	5181 (7)	100.4 (97.7–103.1)
No	2 938 044 (98)	839 (80)	2.9 (2.7–3.1)	69 691 (93)	23.7 (23.5–23.9)
Chorioretinitis					
Yes	744 (0)	74 (7)	994.6 (792.0–1249.1)	56 (0)	75.3 (57.9–97.8)
No	2 988 915 (100)	970 (93)	3.2 (3.0–3.5)	74 816 (100)	25.0 (24.9–25.2)
Hearing loss ^d					
Yes	23 686 (1)	367 (35)	154.9 (139.9–171.6)	2819 (4)	119.0 (114.7–123.5)
No	2 965 973 (99)	677 (65)	2.3 (2.1–2.5)	72 053 (96)	24.3 (24.1–24.5)
cCMV					
Yes				67 (0.1)	64.2 (49.3–79.0)
No				74 805 (99.9)	25.0 (24.9–25.2)

^a Children with cCMV are defined as those with a diagnostic code for cCMV within the first 45 d of birth.

^b ASD is defined as those with ≥ 2 inpatient or outpatient diagnostic codes for ASD codes separated by 6 d occurring at age 1 y and older. All diagnostic codes used to identify cCMV, ASD, and birth related risk factors for ASD are included in Supplemental Table 3.

^c CNS involvement includes brain anomaly, microcephaly, cerebral palsy, epilepsy, or chorioretinitis.

^d Hearing loss is defined as having ≥ 3 medical encounters with diagnostic codes for hearing loss. All diagnostic codes used to identify cCMV, ASD, cooccurring conditions, and hearing loss are included in Supplemental Table 3.

higher among children with a cCMV diagnosis versus those without, even when adjusting for potential confounders (birth year, sex, and region) in the Cox proportional hazard model and when stratifying by preterm birth or LBW. Our study does not address the question of whether children with asymptomatic cCMV infection have a higher risk of ASD because it is not possible to reliably identify such children on the basis of administrative data.⁴² Our sample of children with cCMV appears

heavily weighted toward children with diagnoses for CNS anomaly or injury. Estimates of the overall proportion of CNS diagnoses in a representative cohort of children with cCMV are not available, but the 21% prevalence of cerebral palsy among children with cCMV in our sample is roughly 7 times greater than the prevalence of cerebral palsy in representative samples of children with cCMV¹⁸ and 70 times greater than the population prevalence of cerebral palsy.⁴³




FIGURE 1

Kaplan–Meier curve of ASD diagnosis probability among children with and without cCMV, Medicaid, 2014 to 2020. cCMV was identified by the presence of an International Classification of Diseases, 9th or 10th Revisions, Clinical Modification diagnostic code for cCMV infection (771.1, P35.1) or cytomegaloviral disease (078.5, B25.x) within 45 days of birth. ASD was defined as 2 or more inpatient or outpatient visits with diagnostic codes for ASD (299.0x, 299.8x, 299.9x, F84.0, F84.5, F84.8, F84.9) separated by ≥ 6 days and occurring at a minimum age of 1 year.

Our study is not without limitations, including inherent limitations of studies using administrative databases, notably the misclassification of conditions resulting from clinical underdiagnosis and inconsistent coding practices.^{44,45} Cases identified using these Medicaid administrative data are not generalizable to all infants with cCMV infection. cCMV screening in newborns in the United States is primarily conducted for infants with symptoms suggestive of cCMV, and in places without routine screening for cCMV, most infants with cCMV go undiagnosed.^{42,46} Consequently, the administrative prevalence of cCMV in our sample (3.5 per 10 000) was substantially lower than the population prevalence of cCMV infection in large newborn screening studies in the United States (4.5 per 1000).⁴⁷ Nondifferential misclassification of both cCMV and ASD status as a result of coding or diagnostic errors could lead to underestimation of HRs toward the null.^{2,45} Validation studies for *International Classification of Diseases, Ninth or Tenth Revisions, Clinical*

Modification codes for cCMV in administrative data are lacking, whereas administrative ASD diagnoses in North American children have a high positive predictive value for medically diagnosed ASD.^{31,48} Differential misclassification, on the other hand, could lead to an overestimation of associations.⁴⁵ For example, if children with recognized cCMV are more closely monitored for developmental milestones, they may be more likely to be clinically diagnosed with ASD, as compared with children without cCMV. We had limited ability to adjust for potential confounders, given limitations of Medicaid claims data. The only potential indicator of socioeconomic status of children in the data is eligibility for CHIP versus Medicaid, but we found low continuity of enrollment in CHIP. Finally, although it is possible that requiring at least 4 years of enrollment could introduce selection bias based on factors that influence long-term participation in Medicaid, results were similar using a 1-year enrollment requirement (data not

TABLE 2 Association Between cCMV and ASD, Stratified by Selected Characteristics, Medicaid, 2014 to 2020

Model	HR (95% CI)
All infants	
Unadjusted	2.61 (2.03–3.28)
Adjusted for birth y, region, and sex	2.54 (1.98–3.19)
Strata	
Sex ^a	
Male	1.95 (1.40–2.61)
Female	4.65 (3.09–6.59)
Birth outcomes ^b	
Preterm birth and LBW	2.12 (1.44–2.99)
LBW only	1.79 (0.89–3.14)
Preterm birth only	2.13 (0.91–4.12)
Neither preterm birth nor LBW	2.15 (1.35–3.20)
Any CNS anomaly/injury ^{b,c}	
Yes	1.00 (0.74–1.31)
No	1.60 (0.99–2.40)

^a Stratified analyses are adjusted for birth year and region.
^b Stratified analyses are adjusted for birth year, region, and sex.
^c CNS anomaly/injury includes cerebral palsy, epilepsy, brain anomaly, microcephaly, or chorioretinitis.

shown). It should also be noted that maternal–infant records were not linked; therefore, this analysis could not include potentially confounding pregnancy factors or maternal characteristics that may be associated with ASD risk.

Given the high costs associated with management of ASD in children and adults,⁴⁹ the demonstration of a potentially causal impact of cCMV on risk of ASD could be an important component of the economic impact of cCMV.^{50,51} However, the confirmation of a heightened risk of ASD among children with cCMV infection may require data on prospectively monitored cohorts of children in which cCMV infections are identified through universal screening programs, which have recently been initiated in a few jurisdictions.⁵² The collection of long-term follow-up data for screened cohorts, including information on ASD and other neurodevelopmental diagnoses that are linked to cCMV screening and diagnostic results, could yield more accurate estimates of the association of cCMV infection with ASD risk, both overall and stratified by the presence of cooccurring conditions. Testing for CMV DNA in stored newborn dried blood spots for samples of children with and without ASD could potentially be informative for research purposes.⁵³

Our findings also have clinical implications. Clinicians may want to be proactive in monitoring for early signs of ASD in children with a diagnosis of cCMV, especially those with hearing loss, the risk of which is elevated among both children with cCMV and those with ASD.^{54,55} Making a diagnosis of ASD can be challenging in children who are deaf or hard of hearing.^{56,57} Although cCMV can only be diagnosed through testing of biological specimens collected in the first few weeks of life,⁵⁸ in a few states, clinicians with parental consent might be able to test stored residual dried blood spot specimens for viral DNA for children suspected of having cCMV.⁵⁹ As noted above, a finding of cCMV may prompt additional monitoring for developmental outcomes and need for developmental supports.

CONCLUSIONS

In this cohort study, we found that children with Medicaid or CHIP coverage who had a diagnosis of cCMV were more likely to have a diagnosis of ASD than children without a diagnosis of cCMV. Results of the stratified analysis suggest that a diagnosis of ASD is more common among children with cCMV even in the absence of CNS involvement. Future work examining the prevalence of and risk factors for ASD among children with cCMV identified through a universal screening, as well as studies examining the prevalence of CMV identified on newborn dried blood spot specimens in matched cohorts of children with ASD, could better inform our understanding of this association.

ABBREVIATIONS

ASD: autism spectrum disorder
cCMV: congenital cytomegalovirus
CHIP: Children’s Health Insurance Program
CI: confidence interval
CMV: cytomegalovirus
CNS: central nervous system
HR: hazard ratio
LBW: low birth weight

Copyright © 2024 by the American Academy of Pediatrics

FUNDING: Dr Pesch’s time is supported by funding from Eunice Kennedy Shriver National Institute on Child Health and Development (1 K23 HD108278) and by the Gerber Foundation.

CONFLICT OF INTEREST DISCLOSURES: Dr Pesch serves on the executive board for the National CMV Foundation (unpaid) and is a paid consultant for MedScape/WebMD and DiaSorin Molecular. None of these organizations played any role in the conceptualization, analysis, data interpretation, or writing of this manuscript. The other authors have indicated they have no potential conflicts of interest to disclose.

REFERENCES

1. Dollard SC, Dreon M, Hernandez-Alvarado N, et al. Sensitivity of dried blood spot testing for detection of congenital cytomegalovirus infection. *JAMA Pediatr*. 2021;175(3):e205441
2. Fowler KB, Boppana SB. Congenital cytomegalovirus infection. *Semin Perinatol*. 2018;42(3):149–154
3. Lopez AS, Lanzieri TM, Claussen AH, et al; Congenital Cytomegalovirus Longitudinal Study Group. Intelligence and academic achievement with asymptomatic congenital cytomegalovirus infection. *Pediatrics*. 2017;140(5):e20171517
4. Luck SE, Wieringa JW, Blázquez-Gamero D, et al; ESPID Congenital CMV Group Meeting, Leipzig 2015. Congenital cytomegalovirus: A European expert consensus statement on diagnosis and management. *Pediatr Infect Dis J*. 2017;36(12):1205–1213
5. Lanzieri TM, Leung J, Caviness AC, et al. Long-term outcomes of children with symptomatic congenital cytomegalovirus disease. *J Perinatol*. 2017;37(7):875–880
6. Cushing SL, Purcell PL, Papaionnou V, et al. Hearing instability in children with congenital cytomegalovirus: Evidence and neural consequences. *Laryngoscope*. 2022;132(Suppl 11):S1–S24
7. American Psychiatric Association. *Desk Reference to the Diagnostic Criteria From DSM-5 (R)*. American Psychiatric Association Publishing; 2013
8. Maenner MJ, Warren Z, Williams AR, et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years—Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2020. *MMWR Surveill Summ*. 2023;72(2):1–14
9. Al-Haddad BJS, Oler E, Armistead B, et al. The fetal origins of mental illness. *Am J Obstet Gynecol*. 2019;221(6):549–562
10. Hodges H, Fealko C, Soares N. Autism spectrum disorder: definition, epidemiology, causes, and clinical evaluation. *Transl Pediatr*. 2020;9(Suppl 1):S55–S65
11. Tioleco N, Silberman AE, Stratigos K, et al. Prenatal maternal infection and risk for autism in offspring: A meta-analysis. *Autism Res*. 2021;14(6):1296–1316
12. Jiang HY, Xu LL, Shao L, et al. Maternal infection during pregnancy and risk of autism spectrum disorders: a systematic review and meta-analysis. *Brain Behav Immun*. 2016;58:165–172
13. Shuid AN, Jayusman PA, Shuid N, et al. Association between viral infections and risk of autistic disorder: an overview. *Int J Environ Res Public Health*. 2021;18(6):2817
14. Zawadzka A, Cieřlik M, Adamczyk A. The role of maternal immune activation in the pathogenesis of autism: a review of the evidence, proposed mechanisms and implications for treatment. *Int J Mol Sci*. 2021;22(21):115–116
15. Gentile I, Zappulo E, Riccio MP, et al. Prevalence of congenital cytomegalovirus infection assessed through viral genome detection in dried blood spots in children with autism spectrum disorders. *In Vivo*. 2017;31(3):467–473
16. Garofoli F, Lombardi G, Orcesi S, et al. An Italian prospective experience on the association between congenital cytomegalovirus infection and autistic spectrum disorder. *J Autism Dev Disord*. 2017;47(5):1490–1495
17. Yamashita Y, Fujimoto C, Nakajima E, et al. Possible association between congenital cytomegalovirus infection and autistic disorder. *J Autism Dev Disord*. 2003;33(4):455–459
18. Korndewal MJ, Oudesluys-Murphy AM, Kroes ACM, et al. Long-term impairment attributable to congenital cytomegalovirus infection: a retrospective cohort study. *Dev Med Child Neurol*. 2017;59(12):1261–1268
19. Engman ML, Sundin M, Miniscalco C, et al. Prenatal acquired cytomegalovirus infection should be considered in children with autism. *Acta Paediatr*. 2015;104(8):792–795
20. Maeyama K, Tomioka K, Nagase H, et al. Congenital cytomegalovirus infection in children with autism spectrum disorder: systematic review and meta-analysis. *J Autism Dev Disord*. 2018;48(5):1483–1491
21. Slavuljica I, Kveřtak D, Huszthy PC, et al. Immunobiology of congenital cytomegalovirus infection of the central nervous system—the murine cytomegalovirus model. *Cell Mol Immunol*. 2015;12(2):180–191
22. Han D, Byun SH, Kim J, et al. Human cytomegalovirus IE2 protein disturbs brain development by the dysregulation of neural stem cell maintenance and the polarization of migrating neurons. *J Virol*. 2017;91(17):e00799-17
23. Seleme MC, Kosmac K, Jonjic S, Britt WJ. Tumor necrosis factor alpha-induced recruitment of inflammatory mononuclear cells leads to inflammation and altered brain development in murine cytomegalovirus-infected newborn mice. *J Virol*. 2017;91(8):e01983-16
24. Engman ML, Lewensohn-Fuchs I, Mosskin M, Malm G. Congenital cytomegalovirus infection: The impact of cerebral cortical malformations. *Acta Paediatr*. 2010;99(9):1344–1349
25. Sakamoto A, Moriuchi H, Matsuzaki J, et al. Retrospective diagnosis of congenital cytomegalovirus infection in children with autism spectrum disorder but no other major neurologic deficit. *Brain Dev*. 2015;37(2):200–205
26. Lampi KM, Lehtonen L, Tran PL, et al. Risk of autism spectrum disorders in low birth weight and small for gestational age infants. *J Pediatr*. 2012;161(5):830–836
27. Crump C, Sundquist J, Sundquist K. Preterm or early term birth and risk of autism. *Pediatrics*. 2021;148(3):e2020032300
28. Leung J, Dollard SC, Grosse SD, et al. Valganciclovir use among commercially and Medicaid-insured infants with congenital CMV infection in the United States, 2009–2015. *Clin Ther*. 2018;40(3):430–439.e1
29. Leung J, Grosse SD, Hong K, et al. Changes in valganciclovir use among infants with congenital cytomegalovirus diagnosis in the United States, 2009-2015 and 2016-2019. *J Pediatr*. 2022;246:274–278.e2
30. Leung J, Kennedy JL, Haberling DL, et al. Congenital CMV-coded diagnosis among American Indian and Alaska Native infants in the United States, 2000-2017. *J Immigr Minor Health*. 2020;22(5):1101–1104
31. Straub L, Bateman BT, Hernandez-Diaz S, et al. Validity of claims-based algorithms to identify neurodevelopmental disorders in children. *Pharmacoepidemiol Drug Saf*. 2021;30(12):1635–1642

32. Liu X, Sun X, Sun C, et al. Prevalence of epilepsy in autism spectrum disorders: a systematic review and meta-analysis. *Autism*. 2022;26(1):33–50
33. Nickl-Jockschat T, Habel U, Michel TM, et al. Brain structure anomalies in autism spectrum disorder—a meta-analysis of VBM studies using anatomic likelihood estimation. *Hum Brain Mapp*. 2012;33(6):1470–1489
34. Ameis SH, Catani M. Altered white matter connectivity as a neural substrate for social impairment in autism spectrum disorder. *Cortex*. 2015;62:158–181
35. Hirschberger RG, Kuban KCK, O’Shea TM, et al; ELGAN Study Investigators. Co-occurrence and severity of neurodevelopmental burden (cognitive impairment, cerebral palsy, autism spectrum disorder, and epilepsy) at age ten years in children born extremely preterm. *Pediatr Neurol*. 2018;79:45–52
36. Ferri SL, Abel T, Brodtkin ES. Sex differences in autism spectrum disorder: a review. *Curr Psychiatry Rep*. 2018;20(2):9
37. Werling DM, Geschwind DH. Sex differences in autism spectrum disorders. *Curr Opin Neurol*. 2013;26(2):146–153
38. Tang JW, Li JW, Baulderstone D, Jeyaseelan D. Presenting age and features of females diagnosed with autism spectrum disorder. *J Paediatr Child Health*. 2021;57(8):1182–1189
39. Hull L, Petrides K, Mandy W. The female autism phenotype and camouflaging: a narrative review. *Rev J Autism Dev Disord*. 2020;7:306–317
40. Neuberger I, Garcia J, Meyers ML, et al. Imaging of congenital central nervous system infections. *Pediatr Radiol*. 2018;48(4):513–523
41. Pesch MH, Schleiss MR. Emerging concepts in congenital cytomegalovirus. *Pediatrics*. 2022;150(2):e2021055896
42. Grosse SD, Leung J, Lanzieri TM. Identification of congenital CMV cases in administrative databases and implications for monitoring prevalence, healthcare utilization, and costs. *Curr Med Res Opin*. 2021;37(5):769–779
43. Zablotsky B, Black LI, Maenner MJ, et al. Prevalence and trends of developmental disabilities among children in the United States: 2009-2017. *Pediatrics*. 2019;144(4):e20190811
44. van Walraven C, Austin P. Administrative database research has unique characteristics that can risk biased results. *J Clin Epidemiol*. 2012;65(2):126–131
45. Funk MJ, Landi SN. Misclassification in administrative claims data: quantifying the impact on treatment effect estimates. *Curr Epidemiol Rep*. 2014;1(4):175–185
46. Wilson KL, Shah K, Pesch MH. Inconsistent provider testing practices for congenital cytomegalovirus: Missed diagnoses and missed opportunities. *Int J Neonatal Screen*. 2022;8(4):60
47. Schleiss MR, Rosendahl S, McCann M, et al. Assessment of congenital cytomegalovirus prevalence among newborns in Minnesota during the COVID-19 pandemic. *JAMA Netw Open*. 2022;5(9):e2230020
48. Grosse SD, Nichols P, Nyarko K, et al. Heterogeneity in autism spectrum disorder case-finding algorithms in United States health administrative database analyses. *J Autism Dev Disord*. 2022;52(9):4150–4163
49. Rogge N, Janssen J. The economic costs of autism spectrum disorder: a literature review. *J Autism Dev Disord*. 2019;49(7):2873–2900
50. Grosse SD, Dollard SC, Ortega-Sanchez IR. Economic assessments of the burden of congenital cytomegalovirus infection and the cost-effectiveness of prevention strategies. *Semin Perinatol*. 2021;45(3):151393
51. Retzler J, Hex N, Bartlett C, et al. Economic cost of congenital CMV in the UK. *Arch Dis Child*. 2019;104(6):559–563
52. Ssentongo P, Hehny C, Birungi P, et al. Congenital cytomegalovirus infection burden and epidemiologic risk factors in countries with universal screening: a systematic review and meta-analysis. *JAMA Netw Open*. 2021;4(8):e2120736
53. Kharrazi M, Hyde T, Young S, et al. Use of screening dried blood spots for estimation of prevalence, risk factors, and birth outcomes of congenital cytomegalovirus infection. *J Pediatr*. 2010;157(2):191–197
54. Dumanch KA, Holte L, O’Hollearn T, et al. High risk factors associated with early childhood hearing loss: a 3-year review. *Am J Audiol*. 2017;26(2):129–142
55. Fowler KB, McCollister FP, Sabo DL, et al; CHIMES Study. A targeted approach for congenital cytomegalovirus screening within newborn hearing screening. *Pediatrics*. 2017;139(2):e20162128
56. Ludwig NN, Jashar DT, Sheperd K, et al. Considerations for the identification of autism spectrum disorder in children with vision or hearing impairment: a critical review of the literature and recommendations for practice. *Clin Neuropsychol*. 2022;36(5):1049–1068
57. Beers AN, McBoyle M, Kakande E, et al. Autism and peripheral hearing loss: a systematic review. *Int J Pediatr Otorhinolaryngol*. 2014;78(1):96–101
58. Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. *Lancet Infect Dis*. 2017;17(6):e177–e188
59. Liao EN, Stephans J, Taketa E, et al. Factors associated with congenital cytomegalovirus infection detected by dried blood spot testing in children with hearing loss. *Int J Pediatr Otorhinolaryngol*. 2023;165:111446
60. Inaba Y, Motobayashi M, Nishioka M, et al. Correlation between white matter lesions and intelligence quotient in patients with congenital cytomegalovirus infection. *Pediatr Neurol*. 2016;55:52–57
61. Ivarsson SA, Bjerre I, Vegfors P, Ahlfors K. Autism as one of several disabilities in two children with congenital cytomegalovirus infection. *Neuropediatrics*. 1990;21(2):102–103
62. Karltorp E, Löfkvist U, Lewensohn-Fuchs I, et al. Impaired balance and neurodevelopmental disabilities among children with congenital cytomegalovirus infection. *Acta Paediatr*. 2014;103(11):1165–1173
63. Kawatani M, Nakai A, Okuno T, et al. Detection of cytomegalovirus in preserved umbilical cord from a boy with autistic disorder. *Pediatr Int*. 2010;52(2):304–307

64. Keymeulen A, De Leenheer E, Casaer A, et al. Neurodevelopmental outcome in children with congenital cytomegalovirus infection: a prospective multicenter cohort study. *Early Hum Dev.* 2023;182:105777
65. Lin C-H, Chou I-C, Lee I-C, Hong S-Y. Cytomegalovirus infection in infancy may increase the risk of subsequent epilepsy and autism spectrum disorder in childhood. *Children (Basel).* 2021;8(11):1040
66. Markowitz PI. Autism in a child with congenital cytomegalovirus infection. *J Autism Dev Disord.* 1983;13(3):249–253
67. Meinzen-Derr J, Wiley S, Bishop S, et al. Autism spectrum disorders in 24 children who are deaf or hard of hearing. *Int J Pediatr Otorhinolaryngol.* 2014;78(1):112–118
68. Natsume T, Inaba Y, Osawa Y, Fukuyama T. High incidence of hippocampal abnormalities in pediatric patients with congenital cytomegalovirus infection. *Neuropediatrics.* 2022;53(4):239–245
69. Stubbs EG. Autistic symptoms in a child with congenital cytomegalovirus infection. *J Autism Child Schizophr.* 1978;8(1):37–43
70. Stubbs EG, Budden SS, Burger DR, Vandembark AA. Transfer factor immunotherapy of an autistic child with congenital cytomegalovirus. *J Autism Dev Disord.* 1980;10(4):451–458
71. Stubbs EG, Ash E, Williams CP. Autism and congenital cytomegalovirus. *J Autism Dev Disord.* 1984;14(2):183–189
72. Sweeten TL, Posey DJ, McDougale CJ. Brief report: autistic disorder in three children with cytomegalovirus infection. *J Autism Dev Disord.* 2004;34(5):583–586
73. Yamazaki H, Yamamoto R, Moroto S, et al. Cochlear implantation in children with congenital cytomegalovirus infection accompanied by psycho-neurological disorders. *Acta Otolaryngol.* 2012;132(4):420–427